Expanded eligibility for advanced stroke therapies and new recommendations for diagnosing and treating stroke in children and ...

The American Heart Association/American Stroke Association released its 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke. Stroke published the guideline on Monday.

Expanded eligibility for advanced stroke therapies and new recommendations for diagnosing and treating stroke in children and adults are among the major updates in the new 2026 Guideline for the Early ...

Stroke is the leading cause of long-term disability and preventable disability in the United States. It is also the fifth leading cause of death, killing nearly 130,000 people in the U.S. each year.

In the new American guideline for early management of acute ischemic stroke (AIS), mechanical thrombectomy is expanded, ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...

Please provide your email address to receive an email when new articles are posted on . Researchers engaged in a secondary analysis of the ESCAPE clinical trial in patients with acute ischemic stroke.

The American Academy of Neurology (AAN) has issued a new position statement on "Consent Issues in the Management of Acute Ischemic Stroke," the first update in more than 20 years. The statement was ...

Please provide your email address to receive an email when new articles are posted on . TNKase is the first stroke treatment approved by the FDA in almost 30 years, the manufacturer said. It is ...

In patients with acute ischemic stroke and elevated high-sensitivity cardiac troponin (hs-cTn), dynamic changes in hs-cTn are not helpful in identifying myocardial infarction (MI) or distinguishing MI ...

For acute ischemic stroke within 48 hours of onset, the novel sublingual combination of edaravone (Radicava) with dexborneol appeared to dramatically improve functional outcomes in the phase III TASTE ...